636
Participants
Start Date
May 7, 2019
Primary Completion Date
March 10, 2021
Study Completion Date
March 31, 2021
Tirzepatide
Administered SC
Dulaglutide
Administered SC
Keiseikai Kajiyama Clinic, Kyoto
Akaicho Clinic, Chiba
Medical corporation THY Tokuyama Clinic, Chiba Mihama-ku
National Hospital Organization Kure Medical Center, Kure
Hasegawa Medical Clinic, Chitose
Yuri Ono Clinic, Sapporo
Watanabe Naika Clinic, Nishinomiya
Hayashi Clinic, Nishinomiya
Naka Memorial Clinic, Naka
Hayashi Diabetes Internal Medicine Clinic, Chigasaki-sh
Matoba Diabetes Clinic, Ebina
Takai Naika Clinic, Kamakura
Kanto Rosai Hospital, Kawasaki
H.E.C. Science Clinic, Yokohama
Medical Corporation Heishinkai OCROM Clinic, Suita-shi
Takatsuki Red Cross Hospital, Takatsuki
Senrichuo Ekimae Clinic, Toyonaka
Asano Clinic, Kawagoe
Kawaguchi General Hospital, Kawaguchi
Wakakusa Clinic, Shimotsuke
Seiwa Clinic, Adachi-ku
HDC Atlas Clinic, Chiyoda City
Meiwa Hospital, Chiyodaku
Asahi Life Foundation Adult Disease Research Center, Chuo-ku
Nihonbashi Sakura Clinic, Chuo-ku
Tokyo-Eki Center-building Clinic, Chuo-ku
Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku
Tokyo aSBo Clinic, Chuo-ku
Fukuwa Clinic, Chuo-ku
IHL Shinagawa East One Medical Clinic, Minato-ku
Sato Medical Clinic, Ootaku
Shinjuku Research Park Clinic, Shinjuku
Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku
Tomonaga Clinic, Shinjuku-ku
Shinei Clinic, Suginami
Ikebukuro Metropolitan Clinic, Toshima-ku
Futata Tetsuhiro Clinic, Fukuoka
JR Hiroshima Hospital, Hiroshima
Yoshimura Clinic, Kumamoto
OKAYAMA Medical Center, Okayama
AMC Nishiumeda Clinic, Osaka
Kitada Clinic, Osaka
Nanko Clinic, Osaka
Abe Clinic, Ōita
Suruga Clinic, Shizuoka
Yokohama Minoru Clinic, Yokohama
Eli Lilly and Company
INDUSTRY